In recent months the Biotech Industry has become a hotbed of Merger and Acquisition (M&A) activity and speculation. As large pharmaceuticals face major patent expirations in 2012 they have looked to biotech companies to provide new streams of revenue. Given the limited amount of quality companies, the ones with quality drugs and proven technologies stand to gain the most. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Cardium Therapeutics Inc. and CEL-SCI Corporation.
Access to the full company reports can be found at:
www.FiveStarEquities.com/CXM
www.FiveStarEquities.com/CVM
The U.S. patent system will see a major change for the first time in over 60 years. The America Invents Act (AIA) will see the U.S. patent system transform from a “first to invent” to a “first to file” system. The majority of countries around the world have already adopted the “first to file” system. The AIA will help benefit biotech companies “by enhancing patent quality and the efficiency, objectivity, predictability and transparency of the U.S. patent system.” BIO President and CEO Jim Greenwood stated in a press release: “Small biotechnology companies rely heavily on their patents to attract investment,” and “they will benefit from the improvements to our nation’s patent system made by this legislation,” added Greenwood.
Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.
Cardium is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs. For the fourth quarter ended December 31, 2011, the Company presented a loss from operations of $1.9 million, compared to a $1.5 million loss from operations for the fourth quarter in 2010.
CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body’s natural defense system. Its lead investigational therapy is Multikine, currently being studied in a pivotal global Phase III clinical trial. The company reported that net loss available to shareholders for the quarter ended December 31, 2011 was $4,156,833 versus $6,250,952 during the same quarter a year prior.
Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
www.FiveStarEquities.com/disclaimer
Let us hear your thoughts below.
